HAHadar Arien-Zakay

Hadar Arien-Zakay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hadar Arien-Zakay has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    α-Synuclein-induced Kv4 channelopathy in mouse vagal motoneurons causes non-motor parkinsonian symptoms

    by Wei-Hua Chiu, Lora Kovacheva, Ruth E. Musgrove, Hadar Arien-Zakay, James B. Koprich, Jonathan M. Brotchie, Rami Yaka, Danny Ben-Zvi, Menachem Hanani, Jochen Roeper, et al.

    No disease modifying therapy is currently available for Parkinson’s disease (PD), the second most common neurodegenerative disease. The long non-motor prodromal phase of PD is a window of opportunity for early detection and intervention. However, we lack the pathophysiological understanding to develop selective biomarkers and interventions. By developing a mutant α-synuclein selective-overexpression mouse model of prodromal PD, we identified a cell-autonomous selective Kv4 channelopathy in dorsal motor nucleus of the vagus (DMV) neurons. This functional remodeling of intact DMV neurons leads to impaired pacemaker function in vitro and in vivo, which in turn reduces gastrointestinal motility which is a common, very early symptom of prodromal PD. We show for the first time a causal chain of events from α-synuclein via a biophysical dysfunction of specific neuronal populations to a clinically relevant prodromal symptom. These findings can facilitate the rational design of clinical biomarkers to identify people at risk for PD.

  • Open Access

    Pharmacological Aspects of Vipera xantina palestinae Venom

    by Tatjana Momic, Franziska T. Arlinghaus, Hadar Arien-Zakay, Jeoshua Katzhendler, Johannes A. Eble, Cezary Marcinkiewicz, Philip Lazarovici

    In Israel, Vipera xantina palestinae (V.x.p.) is the most common venomous snake, accounting for several hundred cases of envenomation in humans and domestic animals every year, with a mortality rate of 0.5 to 2%. In this review we will briefly address the research developments relevant to our present understanding of the structure and function of V.x.p. venom with emphasis on venom disintegrins. Venom proteomics indicated the presence of four families of pharmacologically active compounds: (i) neurotoxins; (ii) hemorrhagins; (iii) angioneurin growth factors; and (iv) different types of integrin inhibitors. Viperistatin, a α1β1selective KTS disintegrin and VP12, a α2β1 selective C-type lectin were discovered. These snake venom proteins represent promising tools for research and development of novel collagen receptor selective drugs. These discoveries are also relevant for future improvement of antivenom therapy towards V.x.p. envenomation.


  • Nerve Growth Factor and Human Umbilical Cord Blood-Derived Cells Confer Neurovascular Protection in Ischemia

    by Philip Lazarovici, Hadar Arien-Zakay, Shimon Lecht, Hanan Galski, Esther Shohami, Arnon Nagler, Cezary Marcinkiewicz, Peter I. Lelkes

    Human umbilical cord blood (HUCB), a valuable source for cell therapy of hematologic diseases, was recently found to confer neuroprotection in animal models of brain injury. To explore the neuroprotective properties of HUCB in an ischemic environment, we studied a unique sub-population of collagen-adherent cells. In the presence of nerve growth factor (NGF) and interferon-gamma, these cells differentiate in vitro into a neuronal phenotype (termed HUCBNP). Using a closed-head injury brain trauma model, we recently demonstrated neuroprotective effects of HUCB upon their local injection into the brain. Our in-vitro studies indicated that upon co-culture with ischemia exposed PC12 cells, HUCBNP conferred about 30% neuroprotection, as assessed by decreased lactate dehydrogenase (LDH) release and inhibition of caspase-3 activity. HUCBNP decreased by 95% the level of free radicals in the insulted-PC12 cells, which was in correlation with the appearance of antioxidants and NGF in the medium. HUCBNP-induced neuroprotection also correlated with changes in NGF mRNA expression levels, a process which was blocked by K252a, an antagonist of the NGF-neurotrophin receptor TrkA. To further extend the possible contribution of NGF-mediated protective role, we investigated its neuroprotective mechanisms using PC12 cells and brain capillary endothelial cells exposed to ischemic insult. Pretreatment of the cultures with NGF conferred neuroprotection in a dose- and time-dependent fashion. Time course experiments indicated marked activation of mitogen activated protein kinasas (MAPKs) during the ischemic insult, while treatment of the cultures with NGF inhibited them to different degrees. It appears that both neuronal and endothelial compartments may be protected by NGF under ischemic conditions. Therefore, in future neuroprotection studies, we propose to address additional components of the neurovascular unit such as astrocytes and pericytes in mono-, co- and multi-culture setups. In conclusion, our findings indicate that HUCBNP-induced neuroprotection involves antioxidant(s) and NGF, which by paracrine and/or autocrine route, affects all components of the neurovascular unit.

  • Open Access

    Human Umbilical Cord Blood Stem Cells: Rational for Use as a Neuroprotectant in Ischemic Brain Disease

    by Hadar Arien-Zakay, Shimon Lecht, Arnon Nagler, Philip Lazarovici

    The use of stem cells for reparative medicine was first proposed more than three decades ago. Hematopoietic stem cells from bone marrow, peripheral blood and human umbilical cord blood (CB) have gained major use for treatment of hematological indications. CB, however, is also a source of cells capable of differentiating into various non-hematopoietic cell types, including neural cells. Several animal model reports have shown that CB cells may be used for treatment of neurological injuries. This review summarizes the information available on the origin of CB-derived neuronal cells and the mechanisms proposed to explain their action. The potential use of stem/progenitor cells for treatment of ischemic brain injuries is discussed. Issues that remain to be resolved at the present stage of preclinical trials are addressed.